Table 3.
Explanatory multivariate model of grade III–IV acute GVHD, PFS AND OS
| Variable | N |
Grade III–IV acute GVHD
|
PFS
|
OS
|
|||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Acute GVHD prophylaxis regimen | |||||||
| TAC/μMTX/MMF | 78 | 1.0 | 1.0 | 1.0 | |||
| TAC/MMF | 32 | 2.36 (1.14–4.88) | 0.02 | 1.47 (0.85–2.53) | 0.2 | 1.62 (0.93–2.84) | 0.09 |
| CIBMTR risk | |||||||
| Low | 45 | 1.0 | 1.0 | 1.0 | |||
| Intermediate | 22 | 1.49 (0.54–4.13) | NS | 2.4 (1.11–5.17) | 0.03 | 2.09 (0.93–4.69) | 0.08 |
| High | 43 | 1.5 (0.68–3.32) | NS | 3.6 (1.96–6.6) | <0.0001 | 3.48 (1.88–6.45) | <0.0001 |
| HLA match | |||||||
| Match | 88 | 1.0 | 1.0 | 1.0 | |||
| Mismatch | 22 | 1.8 (0.81–4) | 0.15 | 1.81 (1–3.29) | 0.05 | 1.93 (1.05–3.52) | 0.03 |
| Age, years | |||||||
| 19–39 | 13 | 1.0 | 1.0 | 1.0 | |||
| ⩾40 | 97 | 1.1 (0.32–3.72) | NS | 1.3 (0.58–2.93) | NS | 3.31 (1.01–10.83) | 0.05 |
Abbreviations: CIBMTR = Center for International Blood and Marrow Transplant Research; HR = hazard ratio; MMF = mycophenolate mofetil; μMTX = micro-dose MTX (7.5 mg/m2); TAC = tacrolimus. P>0.2.